Miyahira AK, et al. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020;80(15):1273–96.

Article  PubMed  PubMed Central  Google Scholar 

Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091–103.

Hofman MS, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.

Article  CAS  PubMed  Google Scholar 

Hofman MS, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.

Chi KN, et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382–91.

Sartor O, Castellano Gauna DE, Herrmann K, de Bono JS, Shore ND, Chi KNN, Crosby M, Piulats JM, Flechon A, Wei XX, Mahammedi H, Roubaud G, Studentova H, Ghebremariam S, Kpamegan E, Kreisl TN, Delgoshaie N, Lehnhoff K, Morris MJ, Fizazi K. Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). in ESMO Congress. 2023. LBA13.

Tagawa ST et al. Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). in ESMO Congress. 2019.

Eapen RS, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85(3):217–26.

Privé BM, et al. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021;27(13):3595–601.

Article  PubMed  Google Scholar 

Steinhelfer L, et al. Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. J Nucl Med. 2024;65(1):79–84.

Clement SC, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma–a systematic review. Cancer Treat Rev. 2015;41(10):925–34.

Article  CAS  PubMed  Google Scholar 

Shadman M, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018;36(7):697–703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen AR, et al. 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH. Ann Oncol. 2022;33:S1185.

Article  Google Scholar 

Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci. 2018;11(6):540–52.

Article  PubMed  PubMed Central  Google Scholar 

Ruder S, et al. Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector. J Clin Oncol. 2024;42:161–161.

Article  Google Scholar 

Tagawa ST, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batra JS, et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177)Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38(11):848.e9-848.e16.

Article  CAS  PubMed  Google Scholar 

Niaz MJ, et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2020;25(6):477-e895.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu RF et al. A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer. Nucl Med Commun, 2024.

Sathekge M, et al. (213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099–100.

Article  PubMed  PubMed Central  Google Scholar 

dos Santos JC, et al. Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46(5):1081–91.

Article  PubMed  PubMed Central  Google Scholar 

Parker C, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213–23.

Article  CAS  PubMed  Google Scholar 

Delpassand ES et al. Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Cancer Research, 2024. 84(7_Supplement): p. CT224-CT224.

Tagawa ST, et al. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591. J Clin Oncol. 2024;42(7):842–51.

Article  CAS  PubMed  Google Scholar 

Nauseef JT et al. Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer. Cancer Research, 2023. 83(8_Supplement): p. CT014-CT014.

Sathekge M, et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. J Nucl Med. 2020;61(1):62–9.

Article  CAS  PubMed  Google Scholar 

Sathekge M, et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50(7):2210–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higano CS et al. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. eClinicalMedicine 2023. 60:101993.

Jaggi JS et al. Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys. Int J Rad Oncol Biol Phys. 2006. 64(5):1503–1512.

Müller C, et al. Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Res. 2019;9(1):68.

Article  PubMed  PubMed Central  Google Scholar 

Al-Ibraheem A et al. 161Tb-PSMA Radioligand Therapy: First-in-human SPECT/CT Imaging. J Nuclear Med. 2023: p. jnumed.122.265291.

Hammer S, et al. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res. 2020;26(8):1985–96.

Wright GL, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–34.

Article  PubMed  Google Scholar 

Hope TA, et al. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017;58(1):81–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murga JD, et al. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75(3):242–54.

Article  CAS  PubMed  Google Scholar 

Laverdière J, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37(2):247–52.

Article  PubMed  Google Scholar 

Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys. 1997;37(2):245–6.

Article  CAS  PubMed  Google Scholar 

Emmett L, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563–71.

Article  CAS  PubMed  Google Scholar 

Graf F, et al. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. PLoS ONE. 2014;9(2):e88239.

Article  PubMed  PubMed Central  Google Scholar 

Loap P, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022;8(12):1802–8.

Article  PubMed  PubMed Central  Google Scholar 

Argiris A, et al. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021;22(4):313-323.e1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tuli R, et al. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019;40:375–81.

Article  PubMed  PubMed Central  Google Scholar